Are you over 18 and want to see adult content?
More Annotations
A complete backup of sheskindacrafty.com
Are you over 18 and want to see adult content?
A complete backup of investigativepost.org
Are you over 18 and want to see adult content?
A complete backup of forestryimages.org
Are you over 18 and want to see adult content?
A complete backup of ambythchemical.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of raspberry888.fun
Are you over 18 and want to see adult content?
A complete backup of thainaturelab.com
Are you over 18 and want to see adult content?
A complete backup of equiposparadiscapacitados.com
Are you over 18 and want to see adult content?
Text
guidelines
ABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGE Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI GROUP CALLS FOR #ACTIONOVERWORDS IN THE FIGHT Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.; Parma (Italy), 10 May, 2021 – Chiesi Group, the international research-focused pharmaceuticals and healthcare group, unveils its plan to become carbon neutral by CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolutionOUR AFFILIATES
44 Chipman Hill Suite 1000 Saint John New Brunswick E2L 2A9 CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which has CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
ABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGE Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI GROUP CALLS FOR #ACTIONOVERWORDS IN THE FIGHT Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.; Parma (Italy), 10 May, 2021 – Chiesi Group, the international research-focused pharmaceuticals and healthcare group, unveils its plan to become carbon neutral by CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolutionOUR AFFILIATES
44 Chipman Hill Suite 1000 Saint John New Brunswick E2L 2A9 CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which has CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plcABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGE Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic;ASTHMA AND COPD
Brexin (Piroxicam β-cyclodextrin) is a non-steroidal anti-inflammatory drug indicated for the symptomatic treatment of painful and inflammatory conditions in patients suffering from rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, with a once-daily posology. ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution MANAGEMENT - CHIESI FARMACEUTICI S.P.A Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
MARIA PAOLA CHIESI RECEIVED BY THE PRESIDENT OF THE Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremonyJOB OPPORTUNITIES
Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
PROTALIX BIOTHERAPEUTICS EXPANDS PARTNERSHIP WITH CHIESI Protalix grants Chiesi Ex-US rights for PRX-102, a chemically modified version of the recombinant protein alpha-Galactosidase-A protein; The agreement includes an initial investment of 25 million dollars, as a reimbursement for research costs incurred by Protalix, an additional up to $20 million in development costs and additional regulatory and commercial milestone payments for the U.S. rights EUROPE APPROVES HOLOCLAR®, THE FIRST STEM CELL—BASED Parma/Modena (Italy), February 20, 2015 – The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar ®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea damage.Holoclar ® is manufactured by Holostem Terapie Avanzate (Holostem Advanced Therapies) CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGEHOMECHI SIAMOLA STORIAMISSIONE E VALORIMANAGEMENTSIAMO B CORP E SOCIETÀ BENEFIT Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; CHIESI GROUP CALLS FOR #ACTIONOVERWORDS IN THE FIGHT Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.; Parma (Italy), 10 May, 2021 – Chiesi Group, the international research-focused pharmaceuticals and healthcare group, unveils its plan to become carbon neutral by ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution NEW RECORD FOR THE CHIESI GROUP, WHICH IS CONFIRMED TOP The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.The details were published by the European Patent Office (EPO) when the 2020 official data CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which has CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGEHOMECHI SIAMOLA STORIAMISSIONE E VALORIMANAGEMENTSIAMO B CORP E SOCIETÀ BENEFIT Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; CHIESI GROUP CALLS FOR #ACTIONOVERWORDS IN THE FIGHT Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.; Parma (Italy), 10 May, 2021 – Chiesi Group, the international research-focused pharmaceuticals and healthcare group, unveils its plan to become carbon neutral by ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution NEW RECORD FOR THE CHIESI GROUP, WHICH IS CONFIRMED TOP The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.The details were published by the European Patent Office (EPO) when the 2020 official data CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which hasABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; CONTACTS - CHIESI FARMACEUTICI S.P.A 26/A, Via Palermo (Main entrance: 1, Via Giacomo Chiesi) 43122 Parma – Italy Phone +39 0521 2791 - FAX +39 0521 774468ASTHMA AND COPD
Brexin (Piroxicam β-cyclodextrin) is a non-steroidal anti-inflammatory drug indicated for the symptomatic treatment of painful and inflammatory conditions in patients suffering from rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, with a once-daily posology. ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution MARIA PAOLA CHIESI RECEIVED BY THE PRESIDENT OF THE Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremonyOUR AFFILIATES
44 Chipman Hill Suite 1000 Saint John New Brunswick E2L 2A9SPECIAL CARE
Prodotti & Servizi relative a special care & consumer healthcare. Il marchio Care include prodotti e servizi relativi alla special care e alla salute dei consumatori. CHIESI OUTLINES €350 MILLION INVESTMENT AND ANNOUNCES Market leader in respiratory innovation highlights potentially harmful 1 consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI) ready by end of 2025.. Environmentally-friendly pMDI due to launch by end of 2025 MANAGEMENT - CHIESI FARMACEUTICI S.P.A Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGEHOMECHI SIAMOLA STORIAMISSIONE E VALORIMANAGEMENTSIAMO B CORP E SOCIETÀ BENEFIT Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; CHIESI GROUP CALLS FOR #ACTIONOVERWORDS IN THE FIGHT Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.; Parma (Italy), 10 May, 2021 – Chiesi Group, the international research-focused pharmaceuticals and healthcare group, unveils its plan to become carbon neutral by ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution NEW RECORD FOR THE CHIESI GROUP, WHICH IS CONFIRMED TOP The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.The details were published by the European Patent Office (EPO) when the 2020 official data CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which has CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
CHIESI FARMACEUTICI S.P.ATRANSLATE THIS PAGEHOMECHI SIAMOLA STORIAMISSIONE E VALORIMANAGEMENTSIAMO B CORP E SOCIETÀ BENEFIT Chiesi Farmaceutici S.p.A. CORONAVIRUS. Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando per garantire lacontinuitÃ
CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; CHIESI GROUP CALLS FOR #ACTIONOVERWORDS IN THE FIGHT Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.; Parma (Italy), 10 May, 2021 – Chiesi Group, the international research-focused pharmaceuticals and healthcare group, unveils its plan to become carbon neutral by ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution NEW RECORD FOR THE CHIESI GROUP, WHICH IS CONFIRMED TOP The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.The details were published by the European Patent Office (EPO) when the 2020 official data CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which hasABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; CONTACTS - CHIESI FARMACEUTICI S.P.A 26/A, Via Palermo (Main entrance: 1, Via Giacomo Chiesi) 43122 Parma – Italy Phone +39 0521 2791 - FAX +39 0521 774468ASTHMA AND COPD
Brexin (Piroxicam β-cyclodextrin) is a non-steroidal anti-inflammatory drug indicated for the symptomatic treatment of painful and inflammatory conditions in patients suffering from rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, with a once-daily posology. ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution MARIA PAOLA CHIESI RECEIVED BY THE PRESIDENT OF THE Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremonyOUR AFFILIATES
44 Chipman Hill Suite 1000 Saint John New Brunswick E2L 2A9SPECIAL CARE
Prodotti & Servizi relative a special care & consumer healthcare. Il marchio Care include prodotti e servizi relativi alla special care e alla salute dei consumatori. CHIESI OUTLINES €350 MILLION INVESTMENT AND ANNOUNCES Market leader in respiratory innovation highlights potentially harmful 1 consequences of short-term thinking in rush to introduce policies to switch patients to so-called ‘green inhalers’ as they announce breakthrough environmentally friendly pressurised metered dose inhaler (pMDI) ready by end of 2025.. Environmentally-friendly pMDI due to launch by end of 2025 MANAGEMENT - CHIESI FARMACEUTICI S.P.A Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
ABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution NEW RECORD FOR THE CHIESI GROUP, WHICH IS CONFIRMED TOP The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.The details were published by the European Patent Office (EPO) when the 2020 official data CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. SUSTAINABILITY REPORT Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which hasUGO DI FRANCESCO
Ugo Di Francesco Chief Executive Officer Ugo Di Francesco has been Chief Executive Officer (CEO) of Chiesi Group since 2011, supervising all the global operations CHIESI FARMACEUTICI S.P.AHOMECLINICAL CASESCHIESI CLINICAL TRIAL DATA REQUEST PORTALABOUT USHISTORYMISSION AND VALUES Chiesi Farmaceutici S.p.A. CORONAVIRUS. Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries and implemented strictguidelines
ABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. CHIESI PUBLISHES ITS ANNUAL REPORT: GROUP GENERATES ALMOST €1,992.81 million, around 6,000 employees, an 11% reduction in CO 2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;; The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes Chiesi’s all-round performance: environmental, social and economic; ANNUAL REPORT AND CSR As a B Corp and Benefit Corporation, we are committed to measuring our social and environmental impact with the same accuracy we use to measure our economic results and performance. We are also committed to sharing our work with responsibility, not only in terms of the positive results achieved, but also in terms of the difficulties we encounter and the challenges that hinder our evolution NEW RECORD FOR THE CHIESI GROUP, WHICH IS CONFIRMED TOP The Chiesi Group is the number one Italian pharmaceutical company and ranks fourth among Italian companies across all sectors for filing the highest number of patents.The details were published by the European Patent Office (EPO) when the 2020 official data CHIESI USA, INC. ANNOUNCES FDA APPROVAL OF BRONCHITOL Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol® (mannitol CHIESI GROUP ANNOUNCES CLOSING OF LICENSING TRANSACTION Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announces the closing of the licensing transaction with Santhera Pharmaceuticals. SUSTAINABILITY REPORT Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
UGO DI FRANCESCO
Ugo Di Francesco Chief Executive Officer Ugo Di Francesco has been Chief Executive Officer (CEO) of Chiesi Group since 2011, supervising all the global operations CHIESI ACQUIRES NHCO NUTRITION® SAS AND STRENGTHENS ITS Parma (Italy), September 3 2018 – Chiesi, an international research-focused healthcare Group (Chiesi Group), today announced that it has completed the acquisition of 100% of NHCO Nutrition® SAS (NHCO) shares, a French company specialized in food supplements commercialized in pharmacies, currently active in the French market. NHCO Nutrition® is a high performance company, which hasABOUT US - CHIESI
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. WHAT WE ARE LOOKING FOR Chiesi is looking to partner with companies that are developing innovative therapeutic assets and platforms, that can provide significant benefits to patients, healthcare providers and payers, in our core therapeutic areas.ASTHMA AND COPD
Brexin (Piroxicam β-cyclodextrin) is a non-steroidal anti-inflammatory drug indicated for the symptomatic treatment of painful and inflammatory conditions in patients suffering from rheumatoid arthritis, ankylosing spondylitis and osteoarthritis, with a once-daily posology. CHIESI GROUP RECEIVES DIVERSITY LEADERS AWARD 2021 The Group achieves the 10 th position (just one other Italian company is between the first 10), among the most inclusive companies in Europe and the 1 st position in the Pharmaceutical and Biotechnology sector; ; In Italy, Chiesi ranks 2 nd among the 35 companies qualifying for the ranking.; Parma, November 19 th, 2020 – Chiesi Farmaceutici, a research-focused international pharmaceutical CHIESI GROUP AND APOTEX INC. FINALIZE AGREEMENT FOR Chiesi Group expands distribution network via acquisition for worldwide product rights. Chiesi Group will establish offices inToronto, Canada.
MANAGEMENT - CHIESI FARMACEUTICI S.P.A Autorizzo al trattamento dei miei dati personali ai sensi del D.L. 30giugno 2003 n. 196
CHIESI GROUP IS THE LARGEST PHARMACEUTICAL GROUP IN THE Certified B Corporations meet the highest standards of verified social and environmental performance, transparency and accountability. Chiesi Group receives the B Corp certification from B Lab, a leading global sustainability non-profit body, in recognition of its corporate sustainability practices. CHIESI FARMACEUTICI COMPLETES THE ACQUISITION OF EUROPEAN Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Pharma plc THE LANCET PUBLISHES THE RESULTS OF CHIESI FARMACEUTICI The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy.PAOLO CHIESI
Paolo Chiesi Vice President Paolo Chiesi was born in Parma in 1940. At present, he is Vice President of Chiesi Farmaceutici, president of Chiesi Foundation and head of R&D department of Chiesi* GLOBAL WEBSITE__
*
____
* ENG
ENG
Benvenuti nel sito delgruppo chiesi
* Chi siamo
* La storia
* Missione e Valori
* Management
* B Corp e Società Benefit * Annual e Sustainability Report* Sedi
* I nostri partner
* Aree terapeutiche
* Air
* Rare
* Care
* Ricerca e Sviluppo* Pipeline
* Stabilimenti produttivi* Parma
* Blois
* Santana de ParnaÃba * Global Corporate Development* Lavora con noi
* Persone al centro
* Neo Laureati/Neo Diplomati * Profili con esperienza * Incontra i nostri colleghi * Opportunità professionali* Tips
* F.A.Q.
* SostenibilitÃ
* Il nostro approccio * We ACT - Manifesto della Sostenibilità * Prodotti e pazienti* Processi
* Catena Globale del Valore * Cittadinanza d'Impresa* Chiesi Foundation
* Report di sostenibilitÃ* Area media
* News
* Comunicati Stampa
* Teatro Regio
* Â Â Â Â Â Eventi Teatro Regio * Â Â Â Â Â Festival Verdi* Contatti
IL GRUPPO CHIESI INVITA ALL’AZIONE CONTRO IL CAMBIAMENTO CLIMATICO CON #ACTIONOVERWORDS Chiesi, il più grande gruppo farmaceutico internazionale certificato B Corp, riconferma, attraverso la campagna #ActionOverWords, l’obiettivo di diventare carbon neutral entro il 2035,...Continua a leggere
VAI AL SITO
CORONAVIRUS
Il Gruppo Chiesi monitora costantemente l'evolversi dell'epidemia da COVID-19, adottando provvedimenti che hanno come priorità la salute e il benessere dei pazienti e di tutte le persone dell'Azienda. Team dedicati a livello corporate e in tutte le filiali stanno lavorando in tutti i Paesi in cui sono distribuiti e hanno implementato una serie di attente linee guida volte a garantire la sicurezza di tutti i dipendenti del Gruppo, in linea con quanto disposto dal governo e seguendo le raccomandazioni dell'Organizzazione Mondiale della Sanità .Continua a leggere
NUOVO ASSETTO ORGANIZZATIVO PER CHIESI FOUNDATION Maria Paola Chiesi, Coordinatrice della Fondazione dal 2010, succede nel ruolo di Presidente al dottor Paolo Chiesi. La affianca Massimo Salvadori nel ruolo di Coordinatore di Chiesi Foundation...Continua a leggere
PREV
NEXT
1/
3
Leggi di più
Air
Leggi di più
Rare
Leggi di più
Care
NEWS
Scopri tutto
Il Gruppo Chiesi invita all’azione contro il cambiamento climatico con #ActionOverWords NEWS / 10 Maggio 2021 Chiesi, il più grande gruppo farmaceutico internazionale certificato B Corp, riconferma, attraverso la campagna #ActionOverWords, l’obiettivo di diventare carbon neutral entro il 2035,...CONTINUA
Nuovo assetto organizzativo per Chiesi Foundation PRESS / 03 Maggio 2021 Maria Paola Chiesi, Coordinatrice della Fondazione dal 2010, succede nel ruolo di Presidente al dottor Paolo Chiesi. La affianca Massimo Salvadori nel ruolo di Coordinatore di Chiesi Foundation...CONTINUA
Il Gruppo Chiesi tra le aziende “Leader della Sostenibilità 2021â€in Italia
NEWS / 29 Aprile 2021 Il Gruppo Chiesi, Società Benefit e più grande azienda farmaceutica al mondo certificata B Corp, è tra le 150 aziende italiane “Leader della Sostenibilità ...CONTINUA
Manifesto di sostenibilità Viviamo in un tempo di grandi cambiamenti. Gli equilibri del pianeta, sfruttato oltre i suoi limiti, sono in continua trasformazione. Noi stessi stiamo cambiando il nostro modo di vivere e di pensare la società . A pagarne il prezzo sono i più fragili e gli indifesi: quelli che spesso, in questa grande corsa in avanti, sono lasciatiindietro.
Scopri di più
Chiesi Sustainability report 2019Scarica
CORONAVIRUS
IL GRUPPO CHIESI MONITORA COSTANTEMENTE L'EVOLVERSI DELL'EPIDEMIA DA COVID-19, adottando provvedimenti che hanno come PRIORITÀ LA SALUTE E IL BENESSERE DEI PAZIENTI E DI TUTTE LE PERSONE DELL'AZIENDA. Team dedicati a livello corporate e in tutte le filiali stanno lavorando PER GARANTIRE LA CONTINUITÀ DELLA FORNITURA DEI NOSTRI FARMACI in tutti i Paesi in cui sono distribuiti e hanno implementato una serie di attente linee guida volte a garantire la SICUREZZA DI TUTTI I DIPENDENTI DEL GRUPPO, in linea con quanto disposto dal governo e seguendo le raccomandazioni dell'Organizzazione Mondiale della Sanità . Siamo impegnati, con attenzione costante, per migliorare la qualità della vita delle persone, per questo abbiamo posto le PERSONE AL CENTRO delle nostre azioni, con l'obiettivo di proteggere la salute e il benessere dei nostri dipendenti, pazienti e partner.Trasparenza
Il Gruppo Chiesi, in qualità di impresa del farmaco, collabora con la comunità scientifica attraverso un continuo scambio di conoscenze, che ha portato a importanti progressi nel mondo scientifico a beneficio e tutela della salute dei pazienti, e sempre in linea con i codici e le normative che regolano il nostro settore.Scopri di più
CHIESI Farmaceutici S.p.A.P.IVA 01513360345
Cap. Soc. Euro 75.000.000 i.v. Reg. delle Imprese di ParmaN.15739
REA: 159271
* site map
* Privacy
* cookie
* Credits
* Termini di utilizzo sito web * Termini di utilizzo Facebook * Termini di utilizzo linkedin * Termini di utilizzo Twitter*
CHIESI NEL WEB
seguici su
Copyrights © 2021 CHIESI Farmaceutici S.p.A. CENTRO PREFERENZE PRIVACY*
LA TUA PRIVACY
*
COOKIE PER PUBBLICITÀ MIRATA*
COOKIE STRETTAMENTE NECESSARI*
COOKIE DI PRESTAZIONELA TUA PRIVACY
Quando visiti un qualsiasi sito web, questo può memorizzare o recuperare informazioni dal tuo browser, in gran parte sotto forma di cookie. Queste informazioni potrebbero riguardare te, le tue preferenze o il tuo dispositivo e sono utilizzate in gran parte per garantire il corretto funzionamento del sito. Le informazioni di solito non ti identificano direttamente, ma possono fornire un'esperienza web più personalizzata. Poiché rispettiamo il tuo diritto alla privacy, puoi scegliere di non consentire l’utilizzo di alcune tipologie di cookie. Clicca sulle intestazioni delle diverse categorie per scoprire di più e modificare le impostazioni predefinite. Tuttavia, la disattivazione di alcuni tipi di cookie potrebbe influire negativamente sulla tua esperienza di navigazione del sito e dei servizi offerti su di esso. Ulteriori informazioni COOKIE PER PUBBLICITÀ MIRATA Cookie per pubblicità mirata Questi cookie possono essere impostati tramite il nostro sito dai nostri partner pubblicitari. Possono essere utilizzati da queste aziende per costruire un profilo dei tuoi interessi e mostrarti annunci pertinenti su altri siti. Non memorizzano direttamente informazioni personali, ma sono basati unicamente sull'individuazione del tuo browser e del tuo dispositivo internet. Se non si accettano questi cookie, riceverai una pubblicità meno mirata. COOKIE STRETTAMENTE NECESSARISempre attivi
Questi cookie sono necessari per il funzionamento del sito e non possono essere disattivati ​​nei nostri sistemi. Di solito vengono impostati solo in risposta alle azioni da te effettuate che costituiscono una richiesta di servizi, come l'impostazione delle preferenze di privacy, l'accesso o la compilazione di moduli. È possibile impostare il browser per bloccare o avere avvisi riguardo questi cookie, ma di conseguenza alcune parti del sito non funzioneranno. Questi cookie non archiviano informazioni personali. COOKIE DI PRESTAZIONE Cookie di prestazione Questi cookie ci permettono di contare le visite e fonti di traffico in modo da poter misurare e migliorare le prestazioni del nostro sito. Ci aiutano a sapere quali sono le pagine più e meno popolari e vedere come i visitatori si muovono intorno al sito. Tutte le informazioni raccolte dai cookie sono aggregate e quindi anonime. Se non consenti questi cookie, non sapremo quando hai visitato il nostro sito.BACK BUTTON BACK
Vendor Search
Filter Button
Consent Leg.Interest checkbox label label checkbox label label checkbox label labelClear
checkbox label labelApply Cancel
Conferma le mie scelteConsenti tutti
COOKIE POLICY
Utilizziamo i cookie per personalizzare contenuti, annunci e per analizzare il traffico sul nostro sito. Potremmo anche condividere le tue informazioni di utilizzo del nostro sito con i nostri partner, per finalità pubblicitarie e statistiche. Per gestire o disabilitare questi cookie clicca su "Impostazioni cookie". Per maggiori informazioni ti invitiamo a leggere la nostraCookie policy. Impostazioni cookie Accetta tutti i cookieDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0